Wakui A, Kikuchi K, Yokoyama M, Takahashi K, Yoshida Y, Kaito I, Matsuoka T, Ishikawa M, Goto Y, Ono K, Kikkawa J, Sugahara K, Taima T
Gan To Kagaku Ryoho. 1983 Jul;10(7):1610-23.
A randomized study of 5-FU + adriamycin (the control group) vs 5-FU + adriamycin + levamisole (LMS group) was conducted by an envelope method in 167 patients with advanced gastrointestinal cancer for clinical evaluation of LMS against advanced gastrointestinal cancer. There was a significant increase in survival with the LMS group (p less than 0.05). Median survivals were 3.7 months for the control group and 6.1 months for the LMS group of all patients with gastrointestinal cancer and patients with gastric cancer, respectively. There were no differences in response rate and duration of response between both groups, but the number of PD (progressive disease) cases was significantly smaller in the LMS group than in the control group (p = 0.001). Adverse reactions occurred more frequently in the LMS group, but there was no significant difference in incidence between both groups.
采用信封法对167例晚期胃肠道癌患者进行了一项随机研究，比较5-氟尿嘧啶+阿霉素（对照组）与5-氟尿嘧啶+阿霉素+左旋咪唑（LMS组），以临床评估LMS对晚期胃肠道癌的疗效。LMS组患者的生存率显著提高（p<0.05）。所有胃肠道癌患者及胃癌患者中，对照组的中位生存期分别为3.7个月和6.1个月，LMS组分别为6.1个月和3.7个月。两组的缓解率和缓解持续时间无差异，但LMS组疾病进展（PD）病例数明显少于对照组（p = 0.001）。LMS组不良反应发生频率更高，但两组发生率无显著差异。
